CymaBay Appears Stronger Threat To Ocaliva In PBC Than Ipsen/Genfit

CymaBay and Genfit have been positioning their failed NASH candidates, both PPAR agonists, for approval in second-line primary biliary cholangitis. Analysts call both approvable, but say CymaBay’s drug has a better overall profile.